Article Details
Retrieved on: 2021-03-03 15:56:15
Tags for this article:
Click the tags to see associated articles and topics
Excerpt
The FDA has sent a last-minute notification of an advisory committee review of FibroGen and AstraZeneca's first-in-class anemia candidate roxadustat, ...
Article found on: www.fiercepharma.com
This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.
Sign UpAlready have an account? Log in here